Proteomics and Mass Spectrometry: What Have We Learned About The Heart?

Schaan Chugh¹, Colin Suen¹ and Anthony Gramolini¹,²,*

¹Department of Physiology, University of Toronto and ²Heart and Stroke/Richard Lewar Centre of Cardiovascular Excellence

Abstract: The emergence of new platforms for the discovery of innovative therapeutics has provided a means for diagnosing cardiac disease in its early stages. Taking into consideration the global health burden of cardiac disease, clinicians require innovations in medical diagnostics that can be used for risk stratification. Proteomic based studies offer an avenue for the discovery of proteins that are differentially regulated during disease; such proteins could serve as novel biomarkers of the disease state. For instance, in clinical practice, the abundance of such biomarkers in blood could be correlated with the severity of the disease state. As such, early detection of biomarkers would enable an improvement in patient prognosis. In this review, we outline advancements in various proteomic platforms used to study the disease proteome and their applications to the field of clinical medicine. Specifically, we highlight the contributions of proteomic-based profiling experiments to the analysis of cardiovascular diseases.

1. INTRODUCTION

In clinical practice, diagnosis in the earliest stages of disease progression can prevent further complications and improve patient prognosis. To address this issue, new and innovative means of diagnosing various disease states are essential to ensure that patients are diagnosed early, and treated correctly, in a timely manner. Proteomic-based studies may fill this gap, and discoveries made in the laboratory setting could improve the delivery of healthcare to various patient populations. Generally, proteomic platforms involve the analysis of global expression and function of the entire protein complement [1]. Indeed, the discovery and identification of certain proteins in the disease state may be used as a stepping stone for the assessment of such proteins as potential biomarkers of disease.

Cardiac diseases have been studied through numerous proteomic-based studies. For example, these platforms have been used to analyze myocardial ischemia [2-4], dilated cardiomyopathy [5, 6], hypertrophic cardiomyopathy [7], and heart failure [8-10]. In some cases these strategies may even have aided in the discovery of additional biomarkers of these disease states. Here, we outline progress that has been made in this field and will detail innovative techniques that now potentially could be used to even improve patient prognosis and therapies.

2. CLINICAL PROTEOMICS AT THE BEDSIDE

Clinically-based proteomics has a large potential for the development of strategies which aim to alleviate risk associated with cardiac disease. Biomarkers that are used in clinical practice are highly useful in that they support medical decision making, by complementing other diagnostic tests, such as the medical history, physical examination, and various other special tests. Theoretically, there are three criteria that, if satisfied, would provide an optimal biomarker of the disease state. First, the potential biomarkers must be easily measurable in a short time period at a cost that is practical. Second, elevation of this protein would offer diagnostic information that was not previously present in the absence of the protein. Third, the information obtained would aid in the medical decision making process performed by the clinician [11]. Fulfillment of such criteria encourages follow-up of such a biomarker in other model systems or patient cohort samples. For instance, cardiac troponin I has been previously shown to fulfill such criteria, and further follow-up in patient cohorts is underway. Recently, this approach was utilized to ascertain whether Cardiac Troponin I (CTN I) or Creatine Kinase-Myoglobin (CK-MB) could be used as short-term or long-term markers of risk associated with cardiac surgery [12]. In this study, a patient cohort of 252 individuals who had undergone cardiac surgery was used to analyze levels of these two proteins in blood. Not only was CTN-I shown to be a strong predictor of mortality, but increases in the levels of this protein also correlated well with increases in mortality. Findings from this study support the utilization of patient cohorts as a means to ease the transition from bench to bedside.

3. PROTEOMICS: THE NEW FRONTIER

One of the major goals of proteomic studies is to identify and quantify the entire protein complement of a sample, whether that is a purified protein complex, a cellular organelle component, or an entire tissue. A particular interest is the analysis of global protein expression patterns during a pathological state. Obviously, near-complete protein coverage is vital for the elucidation of disease pathways and for the identification of novel proteins involved in the progression of disease. Traditionally, the most common technique
used to analyze the protein complement involved gel-based separation, a tool that has proven pivotal in studies focused on protein ‘discovery’, yet has limits to its protein coverage. More recently, improved protein coverage has been obtained through gel-free methods. Here, we outline both of these approaches and their contribution to the field of proteomics of the heart.

Gel-Based Separation

The first set of ‘large scale’ studies were the gene expression studies examining mRNA levels through arrays with the underlying assumption that there was a correlation between mRNA levels and protein function [13]. This assumption, however, does not always hold true.

Two-dimensional polyacrylamide gel electrophoresis (2DE) was developed as protein levels could be studied in the absence of mRNA or gene expression analysis [14]. Gel-based separation is powerful in that it can also provide insight onto differential protein regulation in the disease state. In 2DE, a current is applied to a complex sample in a 2D gel to separate proteins on the basis of charge and mass. This effectively resolves proteins on the basis of isoelectric point (pI) followed by separation by mass [15]. Groups have employed 2DE with due success in the proteomic analysis of biomarkers of cardiomyopathy [4] and in the investigation of mechanisms underlying cardiomyopathy [16-18] and diabetic cardiomyopathy [19].

2DE-based proteomic studies are highly useful in that they are capable of quantifying expression of complex protein samples which can contain up to 1000’s of proteins [20]. Furthermore, this technique is advantageous in that in provides information regarding the presence of isoforms or post-translational modifications in addition to protein expres-

Fig. (1). 2D gel electrophoresis reveals proteins that were differentially expressed in PLM KO mice relative to wild-type controls. Spots of interest were excised and subjected to mass spectrometry analysis. Used with permission: Bell et al., Characterization of the phospholemman knockout mouse heart: depressed left ventricular function with increased Na-K-ATPase activity. Am J Physiol Heart Circ Physiol 2008; 294: H613-H621.
played a role in mitochondrial energetics, chaperoning, and stress-responses [28]. These findings provided an unbiased view of potential pathways involved in preconditioning.

Gel based proteomic methods have also benefitted from the development of 2D DIGE (Differential Gel Electrophoresis) whereby up to three protein samples are fluorescently labeled with different fluorochromes and then subjected to gel electrophoresis, followed by scanning and analysis of the gel [29]. Such an approach has been put to use in the analysis of a model of dilated cardiomyopathy [30]. This gel-based method allowed for the identification of a consistent decrease in the phosphorylation of Tropomyosin (Tm). Given that this enzyme is a core component of the actin filament, regulating the interaction of actin and myosin, down-regulation of this protein could have implications for myocardial contractility. This study was highly successful in identifying a potential causes for this type cardiac disease, warranting further investigation in patient cohorts.

Although gel-based methods can be used to separate thousands of proteins and produce easily interpretable visual data, they possess some limitations. Membrane proteins are usually under-represented due to their poor solubility in the sample buffer and resolution in 2DE [31]. In general, gel-based techniques are biased towards the detection of highly abundant proteins and become less effective at detecting hydrophobic proteins and proteins with extreme pI and molecular weight [32]. Additionally, although significant progress has been in 2D gel methods, the lack of automation of extraction, digestion, and analysis of each spot still remains labour-intensive [31]. Alternatively, more groups are now shifting to a gel-free approach, which has been demonstrated to improve protein coverage.

**Gel-Free Separation**

Gel-free systems are being increasingly utilized for proteomic-based experiments. A common gel-free technique is the Multidimensional Protein Identification Technology (MudPIT), pioneered by the Yates group, which utilizes multi-dimensional liquid chromatography as a separation method analogous to 2DE coupled with tandem mass spectrometry (MS/MS) [31, 33]. The technique uses biphasic capillary columns packed with strong cation exchange material (SCX) and reverse phase material (RP) allowing for the separation of protein samples by charge and hydrophobicity [33], (see Fig. 2).

The main advantages of this method over 2D gel approaches are that this approach involves reduced sample handling and thus less potential for sample loss since the column is placed in-line with a tandem mass spectrometer to allow analysis of peptides as they are eluted off the column. For example, this strategy has been applied to the characterization of the yeast proteome [33], several major mouse organs [34-36], embryonic stem cells [37], cytosol [36, 38], mitochondria [39], nucleus [40], and nucleolus [41].

Similarly, Gramolini et al. performed gel-free shotgun sequencing of proteolytic digests of ventricular tissue extracts from phospholamban (PLN-R9C) mutant mice.

![Fig. (2).](image)

A) Ventricular tissue taken from mice is subjected to trypsin digestion. Peptides are then separated on the basis of charge and hydrophobicity. B) Eluted peptides are then electrosprayed into a Linear Ion-Trap Mass Spectrometer via electrospray ionization (ESI). The resultant mass spectra are matched to proteins using database algorithms. C) Increasing salt concentrations, or “salt bumps”, elute peptides from the LC columns providing enhanced peptide separation. Used with Permission: Chugh et al., Large-scale studies to identify biomarkers for heart disease: a role for proteomics? Expert Opin Med Diagn 2009; 3(2): 133-141.
exhibiting dilated cardiomyopathy using high performance multidimensional liquid capillary-scale chromatography (HPLC) coupled to automated data-dependent tandem mass spectrometry (LTQ linear ion trap mass spectrometer) [5]. Of the 6190 proteins identified, 593 were revealed to be differentially expressed between wild-type and R9C hearts. Gel-free separation can now be coupled with sophisticated proteomic technology to allow for direct detection of proteins from complex mixtures. Jullig et al. coupled LC-MS with iTRAQ (Isobaric Tag for Relative and Absolute Quantification) technology in their identification of proteins involved in cardiac mitochondria from diabetic hearts [42]. In these experiments, proteins from samples are covalently tagged at the N-terminus and at amine sidechains with different tags allowing for detection, were pooled together and analyzed by LC-MS to determine which protein sequences are present. This analysis was useful in uncovering 65 differentially regulated proteins in the disease state, emphasizing the involvement of the mitochondria in the progression of diabetes.

Ionization of the Proteome

In addition to the advances that have been made in gel-based and gel-free systems, sophistication of additional platforms has revolutionized the field of clinical proteomics. MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight) mass spectrometry has undergone rapid changes and improvements in recent years, making it a desirable tool for studying the cardiome proteome. This approach utilizes nanosecond laser pulses which vaporize specimens that have been dried and spotted on a target place with a light-absorbing matrix molecule [43]. This platform is advantageous over other MS ionization methods because of its high sensitivity to peptides and proteins of low molecular weight. In addition to the increased sensitivity and mass accuracy, MALDI MS allows for rapid analysis. Tissue sections and whole cells can be directly analyzed, whereas traditional analysis methods require the homogenization and purification of tissue [44]. SELDI (Surface-Enhanced Laser Desorption/Ionization) analysis is a refinement of MALDI in which the metal surface is coated with a specific chemical that takes advantage of antibodies, ionic interactions and hydrophobicity to preselect a subset proteins to be preselected before MS analysis [45]. This is especially useful when the proteome area of interest is already known. For example, immunoaffinity enrichment with different specific Tn monoclonal antibodies were used to validate elevated cTnI as a signature for myocardial infarction, by way of SELDI-TOF MS [45]. This approach has also been used successfully to identify predictive plasma biomarkers of left ventricular remodeling after acute myocardial infarction. This analysis revealed elevated levels of post-translational variants of HpA1 (α1-chain of haptoglobin) in plasma of patients with left ventricular remodeling [46].

MALDI-MS has evolved not only as a powerful discovery tool but more recently as an imaging system. MALDI-IMS (MALDI Imaging Mass Spectrometry) involves the microspotting of tissue samples within a MALDI matrix followed by the acquisition of spectra by mass spectrometry at discrete locations on a predefined “grid” [47]. Each of these spots can be represented as a “pixel” representative of a two dimensional of a tissue sample. They can then be combined to provide a spatial representation of the distribution of a particular protein or molecule [47]. Although this system has yet to be employed for the heart to our knowledge, it has the potential to become an extremely powerful tool for understanding protein expression in pathological states. Evidently, both gel-based and gel-free systems have contributed significantly to the field of clinical proteomics. A brief summary of recent proteomics studies is provided to emphasize the contributions of mass spectrometry based platforms to the investigation of cardiovascular disease (see Table 1).

4. TOOLS FOR VALIDATION

Most biomarker discovery tools such as MS-based analysis still require validation of candidate markers in clinical samples. This calls for a highly specific, high throughput systems that can verify specific protein levels in a large number of samples. Conventional experimental tools, such as protein microarrays and ELISA, rely on antibodies and immunoassays designed to detect specific proteins or peptides. Forward phase protein arrays (FPAs) are widely used in research to quantify the relative abundance of antigens in samples. Antibodies are immobilized on the surface of a chip, which then specifically bind protein antigens from serum samples, cellular lysate, or urine samples. The bound analytes are then detected by the application of a second labeled antibody, usually by means of immunofluorescence [48]. Alternatively, reverse protein arrays (RPAs) do not require immobilized antibodies. Instead, tissue samples are spotted onto a chip’s surface and probed with various antibodies to detect relative abundance [49]. Although RPAs are not commonly used in the assessment of cardiac disease, they have been successfully applied to analyze biomarkers of cancer [50]. Protein microarrays are advantageous in that they allow high-throughput screening in a time-effective manner. ELISA tests are another commonly employed technique used to validate biomarkers. Here, analytes from samples are captured by immobilized antibodies fixed to a plate surface. An enzyme-linked detecting antibody is added, which is then activated by the addition of a substrate that changes colour or fluoresces when catalyzed. Since detection of the analyte is based on the proportion of catalyzed substance, this indirect method amplifies signal and is highly sensitive. Consequently, proteins in the picomolar to nanomolar range can be effectively quantified, making it suitable for clinical applications [48]. However, FPAs, RPAs, and ELISAs all rely on obtaining highly-specific antibodies against known target proteins. Currently, there are limited numbers of highly reliable antibodies available to a small proportion of the proteome. Also, antibody-based systems inevitably suffer from cross-reactivity of antibodies and interference of protein-antibody interactions [51].

Multiple reaction monitoring mass spectrometry (MRM-MS) may have greater potential as a general scientific approach. Traditional MS runs acquire a full-scan of peptides within a defined mass range, and generally detect higher abundance peptides, resulting in a ‘parent ion’. These peptides can trigger a second MS scan where the peptides are fragmented and acquired (daughter ion). The combination of the specific parent mass and the unique fragment ion is used
Table 1. Recent Biomarker and Disease Pathway Elucidation with the Advancement in Various Proteomic Based Technologies

| Biology                                                                 | Discovery                                                                                                                                                                                                 | Proteomic Technique       | Species | Reference |
|------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|---------|-----------|
| Nitrite mediated cardioprotection                                      | Involvement of following mitochondrial proteins: PDIA3, COQ9, ALDH2.                                                                                                                                 | MALDI-TOF MS              | Rat     | [80]      |
| Hypertension induced cardiomyopathy                                    | Decrease in expression of metabolic proteins: adenylate kinase 1, creatine kinase-M, lactate dehydrogenase                                                                                                 | 2DE, Orbitrap MS          | Mouse   | [81]      |
| Protein expression in the aging ventricle                              | Elucidation of protein networks affected: carbohydrate metabolism, cell morphology, cell assembly Significant fluctuations in metabolic proteins                                                                 | iTRAQ                     | Rat     | [82]      |
| Adrenaline and/or reactive oxygen species mediated cardiomyopathy      | Increase in expression of myosin regulatory light chain 2 in both groups, decrease in proteins involved in energetic metabolism in both groups (electron transfer flavoprotein beta subunit)                                             | MALDI-TOF                 | Rat     | [83]      |
| Differentiating protein expression in failing and non-failing hearts    | Identification of known and novel proteins involved in the progression to overt failure, with a corresponding correlation to expression patterns seen in the wild-type cardiac transcriptome, proteome, and phosphoproteome | Reverse Phase Gel-Free Liquid Chromatography | Human   | [84]      |
| Proteomic analysis of chronic heart failure                            | Discovery of heat shock proteins, endoplasmic reticulum stress proteins, oxidative stress proteins, and metabolic enzymes involved in progression to CHF                                                                 | 2DE                       | Rat     | [10]      |
| Proteomic alterations in cardiac disease in frataxin knockout mice      | Decreases in expression of iron dependent complexes in the mitochondrial apparatus, with an increase in citric acid cycle enzymes and catabolic enzymes                                                                 | 2DE                       | Mouse   | [85]      |
| Proteomic analysis of hyperdynamic mouse hearts                        | Identification of differential regulation of myosin light chain isoforms, and post-translational modifications.                                                                                           | 2DE, MALDI TOF, LC-MS/MS  | Mouse   | [86]      |
| Differential expression of ferritin light chain in coronary atherosclerosis | Increased expression of ferritin light chain in diseased coronary arteries, confirming that there is an increase in iron during CAD                                                                          | 2DE                       | Human   | [79]      |
| Isolation of cardiac troponins from biological samples                 | A unique method for the extraction of cardiac troponins from the left ventricle of patients with cardiovascular disease is described                                                                          | Affinity chromatography, MALDI-TOF | Human   | [87]      |
| Proteomic profiling of chronic heart failure                           | Discovery of upregulation in HSP70 in patients with arrhythmogenic right ventricular cardiomyopathy relative to control samples                                                                          | 2DE, MS                   | Human/Rat | [9]       |
| Investigation of post-translational modifications of cardiac troponin I | Proteomic approach used to understand the complex interplay between phosphorylation and proteolysis of cardiac troponin I, to strengthen its role as a biomarker                                                    | ESI/FTMS                  | Human   | [88]      |
| Proteomic analysis of diabetic myocardial proteome                      | Profiling of the diseased cardiac proteome allowed for the analysis of free-radical production as well as antioxidant defense mechanisms.                                                             | 2DE, MALDI-TOF MS         | Rat     | [89]      |
| Proteomic analysis of ischemia/reperfusion model                        | Validated isolated organ perfusion as a potential diagnostic tool for biomarker discovery                                                                                                                  | 2DE LC-MS/MS              | Rat     | [4]       |
| Proteomic analysis of ischemia/reperfusion model                        | Identified 25 mitochondrial proteins involved in mitochondrial respiratory chain and energy metabolism differentially expressed in ischemia-reperfusion hearts                                               | 2DE MALDI-TOF             | Rabbit  | [3]       |
| Proteomic analysis of myocardial infarction                            | Gel-free analysis of cardiac troponin isoforms from blood samples of patients with acute myocardial infarctions                                                                                           | SELDI-TOF                 | Human   | [2]       |
to selectively identify a protein or peptide. As an alternative to this ‘data-dependent’ platform, MRM-MS can be programmed to target a specific peptide subpopulation by monitoring for only selected precursors representative of a protein of interest. This provides high selectivity by monitoring several transitions for a particular peptide by chromatographic elution [52]. However, the most important advantage of this approach is that this method does not require an antibody, only knowledge of the parent/daughter ion signatures. As such, numerous quantitative assays can be developed and monitored for proteins where no reagents currently exist. MRM has been applied successfully to quantify protein expression [53], to elucidate cellular signaling pathways in the EGFR network [52], and to discover serum biomarkers to assess severity of rheumatoid arthritis [54].

In addition to the advantages of proteomic-based studies, there are challenges which may stand in the way of achieving optimal results. Sample complexity is a major concern that must be taken into account in all proteomic based studied. Cardiac tissue samples, for example, may contain a dynamic range in protein abundance, with sarcomeric proteins being present in much higher quantities than other cardiac resident tissue proteins. This complexity is problematic for mass spectrometry analysis. Since peptides are selected for analysis at the collision cell of the mass spectrometer, peptides present in high amounts interfere with accurate identification of lower abundance peptides. Thus, there may be a misrepresentation of peptide sequences within a given sample. In their study, Kuster et al. reported that potentially hundreds of thousands of peptides may be present following digestion of a sample, which could lead to undersampling of peptide ions [55]. This overwhelming amount of peptide sequences arises predominantly from the large number of unique protein sequences owing to post-transcriptional modifications, processing of proteolytic segments, and alternative splicing of peptide sequences, as well as genetic variation among individuals. To address this issue, techniques must be set in place to reduce sample complexity [56]. In cardiac samples, for example, pre-fractionation is one such procedure that shows promise in minimizing sample complexity as it analyzes various cellular fractions independently, after which abundance levels can be compiled in each separate fraction [5, 57, 58]. The utility of this approach was confirmed by Havugimana et al. who performed a proteomic analysis of cardiac samples that were pre-fractionated and those that were not. They discovered a marked increase in protein coverage in samples that had been pre-fractionated versus those that had not [59]. Sample complexity is also an issue of concern in blood. Albumin and immunoglobins, namely IgG, represent 99% large portion of the proteome [60]. Because there are myriads of undiscovered proteins in blood that could serve as biomarkers of disease, albumin and IgG must be depleted prior to in depth analysis. To date, various techniques have been described to achieve this goal [61, 62]. Another potential challenge of proteomic based experiments lay in sample selection. Many proteomic studies which analyze levels of proteins in blood make the assumption that there is a similar expression pattern in the diseased tissue. This hypothesis does not always hold true, since a protein biomarker has been significantly diluted from its journey from diseased tissue to body fluids such as blood [63]. However, as technological improvements in mass spectrometry and pre-fractionation continue to improve sensitivity and specificity and overcome these challenges novel biomarkers of disease will be identified with greater confidence.

### 5. MYOCARDIAL ISCHEMIA

Proteomic platforms have also been exploited in order to gain insight on to disease pathways involved in the pro-

| Biology | Discovery | Proteomic Technique | Species | Reference |
|---------|-----------|---------------------|---------|-----------|
| Clinical detection of BNP in patients with congestive heart failure | Developed a surface affinity chip to enhance enrichment, separation, and detection of BNP in human plasma. | MALDI-TOF | Human | [8] |
| Innovative proteomic technique for the analysis of myocardial hibernation | Demonstrated improvement of a label-free LC-Orbitrap method over a parallel study using 2DE for expression profiling of myocardial mitochondrial proteins | LC-Orbitrap | Pig | [90] |
| Proteomic analysis of rat model of heart failure | Identified and quantified changes in cardiac mitochondrial proteins | iTRAQ MuDPIT MS/MS | Rat | [42] |
| Comparative proteomic profiling of a rat model of heart failure resulting from cardiac hypertrophy | Changes in 33 left ventricular mitochondrial proteins in pre-hypertensive/hypertensive stages of cardiac hypertrophy | 2DE MALDI-TOF/TOF (tandem MS) | Rat | [91] |
| Identification of Hpc1 variants involved in the progression to heart failure | Post-translational variants of Hpc1 as plasma biomarkers for left ventricular remodeling from patients with acute myocardial infarctions | SELDI-TOF | Human | [46] |
| Comparative proteomic profiling of a mouse model of dilated cardiomyopathy | Large-scale shotgun analysis revealed 593 differentially regulated proteins in mice with dilated cardiomyopathy, including key apoptotic proteins | LC-MS, MuDPIT | Mouse | [5] |
pression of myocardial ischemia. During myocardial ischemia the normal balance between oxygen supply and demand is compromised, with the latter dominating. Taking into consideration the fact that the heart requires a continuous supply of oxygen to carry out normal function, a decrease in the oxygen available could lead to myocardial tissue damage.

Patients who have myocardial ischemia often present with angina, dyspnea, or diaphoresis which would lead a clinician to pursue further diagnostic tests. Investigations may be performed at rest or upon exertion, to ascertain the severity of the disease. Traditionally, exercise testing in conjunction with electrocardiography has been a standard test for the initial assessment of patients suspected of having some degree of ischemia. However, new clinical diagnostics are needed to complement these tests to improve the prognosis of this disease state.

Proteins used as markers can be part of a signaling pathway activated during disease progression, or simply an unrelated protein that is overexpressed in the disease state. Nevertheless, both groups of proteins serve an important purpose in the diagnosis of ischemia. Eugene Braunwald pointed out that biomarkers can be classified into six groups: inflammation, oxidative stress, extracellular-matrix remodeling, neurohormones, myocyte injury, and myocyte stress. Markers of myocardial ischemia generally fall into the group of myocyte injury, such as ischemia-modified albumin [64, 65], unbound free fatty acid [66], NT-proBNP/BNP [67-69], and IL-6 [70]. Exploration into various other categories, such as inflammatory markers or proteins involved in remodeling, could offer a new and innovative means to diagnose this disease process in the early stages. Proteomic strategies are now being used to uncover proteins that would have not been identifiable in the past.

During myocardial ischemia, myocyte stress leads to mitochondrial damage. This hallmark feature is beginning to be exploited to determine additional markers of this disease state. Weiss et al. describe the phenomenon of Mitochondrial Permeability Transition (MPT), occurring during ischemia/reperfusion, during which there is irreversible injury to the mitochondria [71]. Here, an increase in the permeability of specialized mitochondrial pores leads to swelling of the mitochondrial matrix and subsequent rupture of the outer membrane with a corresponding release of apoptotic proteins. However, there is much to be discovered in relation to activated protein pathways and other key post-translational modifications that occur during this disease state. In an attempt to fill this gap, Chen et al. used a proteomic approach to determine which proteins were differentially regulated in ischemic hearts [72]. Specifically, proteins were first tagged with fluorescent dyes and then resolved on a 2D gel, allowing for visual detection of alterations in protein expression. Spots of interest were then excised from the gel and underwent subsequent analysis using liquid chromatography mass spectrometry. This approach allowed for the discovery of the mitochondrial protein, aldehyde dehydrogenase type 2 (ALDH2), a cardioprotective protein. In a similar endeavor, Jacquet et al. used a similar approach to improve clinical diagnosis of Acute Myocardial Infarctions (AMI) [73]. Here, gel electrophoresis was used to determine which proteins were abundant in cardiac samples taken from mice exposed to ischemic conditions. In addition to previously established biomarkers, this group showed cardiac myosin binding protein C as a potential biomarker of AMI. Of interest, the expression of this protein far exceeded that of certain previously established biomarkers of AMI, emphasizing the utility of this protein for clinical diagnosis. Indeed, this study has set the stage for further analysis of this protein in patient cohort samples as well as its involvement in pathways following myocardial infarction.

Blood contains a repository of unexplored biomarkers which, if identified, have the potential to revolutionize the treatment of various disease forms [74]. When subjected to stress, as in myocardial ischemia, cells often secrete specific proteins into the blood which reflect the physiological state. Highly impactful are proteomic experiments performed directly on blood samples taken from human patients who suffer from ischemia. Those proteins that would be found to be differentially expressed in diseased blood would be further pursued as potential biomarkers. This approach has been applied effectively to samples taken from patients with inducible ischemia [75]. Following resolution by liquid chromatography, mass spectrometry was performed to determine which proteins had altered expression in this disease state. Six metabolites were found to possess significant alteration during myocardial ischemia. Of these, 193 and MET 121 to be increased during myocardial ischemia, whereas MET 200, gamma aminobutyric acid, uric acid, and citric acid were decreased in the diseased state. As discussed previously, examination of proteins in blood presents many technical challenges that need to be overcome to arrive at accurate results. Furthermore, the assumption that protein expression patterns in tissue and blood are always concordant, has been a point of contention [76]. Nevertheless, Zhang et al. demonstrated that, in fact, expression patterns in both samples are similar. [77]. Here, they show that there may not be a linear relationship between changes in protein expression in tissue and alterations in blood [76]. By examining glycosylation patterns of peptides, using mass spectrometric analysis, they were able to confirm that many proteins detected in tissue were also present in blood. However, biomarkers showing promise of being used in a clinical setting should be analyzed in tissue samples to ensure concordant expression patterns, thereby providing a powerful marker of the disease state.

Well established as a major cause of myocardial ischemia is an increase in oxygen demand in the presence of fixed coronary vessel narrowing. Physical obstruction can be attributed to the formation of atherosclerotic plaques within these arteries. As low-density lipoproteins (LDL) and other inflammatory molecules accumulate in the coronary arteries, plaques will often destabilize which can lead to a rupture and thrombosis. Given that atherosclerosis is the leading cause of myocardial ischemia, various proteomic-based studies have analyzed atherosclerotic plaques. Specifically, proteins that have significant alterations in expression in such tissue samples could be further studied as potential markers in patients who have ischemia. For instance, a proteomic strategy was utilized in the determination of proteins that were differentially expressed in atherosclerotic tissue samples, relative to controls [78]. Notably, actin, tropomyosin-like
proteins, and two glycoproteins were identified in this study. A subsequent analysis of patients who had coronary artery disease was performed whereby coronary arteries from diseased patients and matched controls were used [79]. Their proteomic platform, involving 2D-gel electrophoresis followed by mass spectrometric analysis, revealed ferritin light chain to be overexpressed. This result was highly significant as this protein likely contributes to the progression of myocardial ischemia. Within atherosclerotic plaques, the generation of reactive oxygen species has been studied in depth as such radicals modify the lipids and proteins of Low Density Lipoproteins. Ferritin light chain may act by altering the generation of reactive oxygen species, thereby regulating the growth of atherosclerotic plaques. This promising biomarker would benefit from validation in additional clinical studies which include patients with signs and symptoms of early stage myocardial ischemia.

6. CONCLUSION
Given the overall health burden felt by cardiomyopathy on a global scale, there still remains an urgent need for new and innovative therapies for these diseases. Proteomic-based studies may be able to provide these markers of disease and new therapeutic avenues that may one day be translated into the clinical setting where they will be used regularly in the diagnosis and treatment of cardiac disease. Obviously, the transition from bench to bedside is not an easy one, and must be facilitated by subsequent, carefully designed, clinical trials.

7. ACKNOWLEDGMENTS
Work in our group was supported by the Heart and Stroke Foundation of Ontario (#T-6281), Canadian Institutes of Health Research (MOP-84267), Genome Canada through the Ontario Genomics Institute, Canadian Foundation for Innovation, Connaught Foundation, and the Heart and Stroke/Richard Lewar Centre of Cardiovascular Excellence. AOG is a Canada Research Chair, and AOG is a New Investigator of the Heart and Stroke Foundation of Canada. S.Chugh and A. Gramolini were involved in the conception, design, and writing the manuscript. C.Suen was involved in drafting and writing the manuscript.

ABBREVIATIONS

| Abbr  | Definition                          |
|-------|------------------------------------|
| CTN I | Cardiac Troponin I                 |
| CK-MB | Creatine Kinase-Myoglobin          |
| 2D-GE | Two Dimensional-Gel Electrophoresis |
| pI    | Isoelectric Point                  |
| DIGE  | Differential Gel Electrophoresis   |
| Tm    | Tropomyosin                        |
| PEDF  | Pigment-Epithelium Derived Factor  |
| MudPIT| Multidimensional Protein Identification Technology |
| MS    | Mass Spectrometry                  |
| SCX   | Strong Cation Exchange             |
| RP    | Reverse Phase                      |
| PLN-R9C| Phospholamban-Arginine to Cysteine Mutation |
| HPLC  | High Performance Liquid Chromatography |
| iTRAQ | Isobaric Tag for Relative and Absolute Quantification |
| LC-MS | Liquid Chromatography-Mass Spectrometry |
| MALDI-TOF| Matrix-Assisted Laser Desorption-Ionization Time-Of-Flight |
| SELDI | Surface-Enhanced Laser Desorption/Ionization |
| TOF   | Time of Flight Surface-Enhanced Laser Desorption/Ionization |
| Hpa1  | α1-chain of haptoglobin             |
| IMS   | Imaging Mass Spectrometry          |
| PDIA3 | Protein Disulfide Isomerase family A, member 3 |
| COQ9  | Coenzyme Q9                        |
| ALDH2 | Aldehyde Dehydrogenase 2          |
| HSP70 | Heat Shock Protein 70              |
| ELISA | Enzyme Linked Immunosorbent Assay  |
| FPA   | Forward Protein Assay              |
| RPA   | Reverse Protein Assay              |
| MRM-MS| Multiple reaction monitoring mass spectrometry |
| EGFR  | Epidermal Growth Factor Receptor   |
| BNP   | Brain Naturietic Peptide           |
| IL-6  | Interleukin-6                      |
| MPT   | Mitochondrial Permeability Transition |
| AMI   | Acute Myocardial Infarction        |
| LDL   | Low Density Lipoprotein            |
| NO    | Nitric Oxide                       |
| PLM-KO| Phospholemman-Knockout             |

REFERENCES

[1] Kislinger T, Emili A. Going global: protein expression profiling using shotgun mass spectrometry. Curr Opin Mol Ther 2003; 5(3): 285-93.
[2] Peronnet E, Becquart L, Poirier F, Cubizolles M, Choquet-Kastylevsky G, Jolivet-Reynaud C. SELDI-TOF MS analysis of the Cardiac Troponin I forms present in plasma from patients with myocardial infarction. Proteomics 2006; 6(23): 6288-99.
[3] Kim N, Lee Y, Kim H, et al. Potential biomarkers for ischemic heart damage identified in mitochondrial proteins by comparative proteomics. Proteomics 2006; 6(4): 1237-49.
[4] Koomen JM, Wilson CR, Guthrie P, Androlewicz MJ, Choquet-Kastylevsky G, Jolivet-Reynaud C. SELDI-TOF MS analysis of the Cardiac Troponin I forms present in plasma from patients with myocardial infarction. Proteomics 2006; 6(23): 6288-99.
[5] Gramolini AO, Kislinger T, Alikhani-Kooperi R, et al. Comparative proteomics profiling of a phospholamban mutant mouse
model of dilated cardiomyopathy reveals progressive intracellular stress responses. Mol Cell Proteomics 2008; 7(3): 519-33.

[6] Weekes J, Wheeler CH, Yan JX, et al. Bovine dilated cardiomyopathy: proteomic analysis of an animal model of human dilated cardiomyopathy. Electrophoresis 1999; 20(4-5): 898-906.

[7] Buscemi N, Murray C, Doherty-Kirby A, Lajoie G, Sussman MA, Van Eyk JE. Myocardial subproteomic analysis of a constitutively active Rac1-expressing transgenic mouse with lethal myocardial hypertrophy. Am J Physiol 2005; 289(6): H2325-33.

[8] Chen YQ, Bi F, Wang SQ, Xiao SJ, Liu JN. Porous silicon affinity chips for biomarker detection by MALDI-TOF-MS. J Chromatogr B 2008; 875(2): 502-8.

[9] Wei Y, Huang XY, Shen Y, et al. Proteomic analysis reveals significant elevation of heat shock protein 70 in patients with chronic heart failure due to arrhythmogenic right ventricular cardiomyopathy. Mol Cell Biochem 2009; 332(1-2): 103-11.

[10] Cieniewski-Bernard C, Mulder P, Henry JP, et al. Proteomic analysis of left ventricular remodeling in an experimental model of heart failure J Proteome Res 2008; 7(11): 5004-16.

[11] Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007; 115(8): 949-52.

[12] Bignami E, Landoni G, Cresczenzi G, et al. Role of cardiac biomarkers (troponin I and CK-MB) as predictors of quality of life and long-term outcome after cardiac surgery. Ann Card Anaesth 2009; 12(1): 22-6.

[13] McGregor E, Dunn MJ. Proteomics of heart disease. Hum Mol Gen 2003; 12 Spec No 2: R135-44.

[14] O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975; 250(10): 4007-21.

[15] McGregor E, Dunn MJ. Proteomics of the heart: unraveling disease. Care Res 2006; 98(3): 309-21.

[16] Lang SC, Elsasser A, Scheller C, et al. Myocardial preconditioning and remote renal preconditioning—identifying a protective factor using proteomic methods? Basic Res Cardiol 2006; 101(2): 149-58.

[17] Yan L, Vatner DE, Kim SJ, et al. Autophagy in chronically ischemic myocardium. Proc Natl Acad Sci USA 2005; 102(39): 13807-12.

[18] Faber MJ, Dalinghaus M, Lankhuizen IM, et al. Proteomic changes in the pressure overloaded right ventricle after 6 weeks in young rats: correlations with the degree of hypertrophy. Proteomics 2005; 5(10): 2519-30.

[19] Shen X, Zheng S, Thongboonkerd V, et al. Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes. Am J Physiol Endocrinol Metab 2004; 287(5): E896-905.

[20] Gorg A, Weiss W, Dunn MJ. Current two-dimensional electro-phoresis technology for proteomics. Proteomics 2004; 4(12): 3665-85.

[21] Barnoun K. Two-dimensional gel electrophoresis for analysis of protein complexes. Methods Mol Biol 2004; 261: 479-98.

[22] Rabilloud T. Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains. Proteomics 2003; 3(6): 815-20.

[23] Robichaud S, Lalou M, Udenberg T, Schulz R, Sawicki G. Proteomics analysis of changes in myocardial proteins during endotoxemia. J Proteomics 2009; 72(4): 648-55.

[24] Bell JR, Kennington E, Fuller W, et al. Characterization of the phospholemman knockout mouse heart: depressed left ventricular function with increased Na-K-ATPase activity. Am J Physiol 2008; 294(2): H613-21.

[25] Arrell DK, Elliott ST, Kane LA, et al. Proteomic analysis of pharmacological preconditioning: novel protein targets converge to mitochondrial metabolism pathways. Circ Res 2006; 99(7): 706-14.

[26] Marouga R, David S, Hawkins E. The development of the DIGE system: 2D fluorescence difference gel electrophoresis analysis. Anal Bioanal Chem 2005; 382(3): 669-78.

[27] Warren CM, Arteaga GM, Rajan S, Ahmed RP, Wieczorek DF, Solaro RJ. Use of 2-D DIGE analysis reveals altered phosphorylation in a tropomyosin mutant (Glu54Lys) linked to dilated cardiomyopathy. Proteomics 2008; 8(1): 100-5.

[28] Kline KG, Wu CC. MudPIT analysis: application to human heart tissue. Methods Mol Biol 2009; 528: 281-93.

[29] Edwards AV, White MY, Cordwell SJ. The role of proteomics in clinical cardiovascular biomarker discovery. Mol Cell Proteomics 2005; 7(10): 1824-37.

[30] Washburn MP, Wolters D, Yates JR, 3rd. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001; 19(3): 242-7.

[31] Cutillas PR, Vanhaesebroeck B. Quantitative profile of five murine core proteomes using label-free functional proteomics. Mol Cell Proteomics 2007; 6(9): 1560-73.

[32] Kisliger T, Cox B, Kannan A, et al. Global survey of organ and organelle protein expression in mouse: combined proteomic and transcriptomic profiling. Cell 2006; 125(1): 173-86.

[33] Shi R, Kumar C, Zougman A, et al. Analysis of the mouse liver proteome using advanced mass spectrometry. J Proteome Res 2007; 6(8): 2963-72.

[34] Graumann J, Hubner NC, Kim JB, et al. Stable isotope labeling by amino acids in cell culture (SILAC) and proteome quantitation of mouse embryonic stem cells to a depth of 5,111 proteins. Mol Cell Proteomics 2008; 7(4): 672-83.

[35] Shin YK, Lee HJ, Lee JS, Paik YK. Proteomic analysis of myocardial ischemic injury by liquid-biased-two-dimensional column chromatography. Proteomics 2006; 6(4): 1143-50.

[36] Mootha VK, Burtneskamp J, Olsen J, et al. Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria. Cell 2003; 115(5): 629-40.

[37] Schirmer EC, Floros L, Guan T, Yates JR, 3rd, Gerace L. Nuclear membrane proteins with potential disease links found by subtractive proteomics. Science 2003; 301(5658): 1380-2.

[38] Andersen JS, Lam YW, Leung AK, et al. Nuclear proteome dynamics. Nature 2005; 433(7021): 77-83.

[39] Jullig M, Hickey AJ, Chai CC, et al. Is the failing heart out of fuel or a worn engine running rich? A study of mitochondria in old spontaneously hypertensive rats. Proteomics 2008; 8(12): 2556-72.

[40] Faber MJ, Dalinghaus M, Lankhuizen IM, et al. Proteomic changes in the pressure overloaded right ventricle after 6 weeks in young rats: correlations with the degree of hypertrophy. Proteomics 2005; 5(10): 2519-30.

[41] Shibata Y, Zheng S, Thongboonkerd V, et al. Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes. Am J Physiol Endocrinol Metab 2004; 287(5): E896-905.

[42] Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004; 4(12): 3665-85.

[43] Barnoun K. Two-dimensional gel electrophoresis for analysis of protein complexes. Methods Mol Biol 2004; 261: 479-98.

[44] Righetti PG, Castagna A, Antonioli P, Boschetti E. Prefractionation techniques in proteome analysis: the mining tools of the third millennium. Electrophoresis 2005; 26(2): 297-319.

[45] Guo Y, Fu Z, Van Eyk JE. A proteomic primer for the clinician. Proteomics 2007; 7(11): 2348-63.

[46] Stanley BA, Neevera I, Brown HA, Van Eyk JE. Optimizing protein solubility for two-dimensional gel electrophoresis analysis of human myocardium. Proteomics 2003; 3(6): 815-20.

[47] Robichaud S, Lalou M, Udenberg T, Schulz R, Sawicki G. Proteomics analysis of changes in myocardial proteins during endotoxemia. J Proteomics 2009; 72(4): 648-55.

[48] Bell JR, Kennington E, Fuller W, et al. Characterization of the phospholemman knockout mouse heart: depressed left ventricular function with increased Na-K-ATPase activity. Am J Physiol 2008; 294(2): H613-21.

[49] Arrell DK, Elliott ST, Kane LA, et al. Proteomic analysis of pharmacological preconditioning: novel protein targets converge to mitochondrial metabolism pathways. Circ Res 2006; 99(7): 706-14.

[50] Marouga R, David S, Hawkins E. The development of the DIGE system: 2D fluorescence difference gel electrophoresis analysis. Anal Bioanal Chem 2005; 382(3): 669-78.

[51] Warren CM, Arteaga GM, Rajan S, Ahmed RP, Wieczorek DF, Solaro RJ. Use of 2-D DIGE analysis reveals altered phospho-
[56] Gerszten RE, Accurso F, Bernard GR, et al. Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. Am J Physiol 2008; 295(1): L16-22.

[57] Kislinger T, Rahman K, Radulovic D, Cox B, Rossant J, Emili A. PRISM, a generic large scale proteomic investigation strategy for mammals. Mol Cell Proteomics 2003;2(2):96-106.

[58] Sandhu C, Connor M, Kislinger T, Slingerland J, Emili A. Global protein shotgun expression profiling of proliferating mcf-7 breast cancer cells. J Proteome Res 2005; 4(3): 674-89.

[59] Havugimana PC, Wong P, Emili A. Improved proteomic discovery by sample pre-fractionation using dual-column ion-exchange high performance liquid chromatography. . J Chromatogr 2007; 847(1): 54-61.

[60] Horvatovich P, Govorukhina N, Bischoff R. Biomarker discovery by proteomics: challenges not only for the analytical chemist. Analyst 2006; 131(11): 1193-6.

[61] Seam N, Gonzales DA, Kern SJ, Horton GL, Hoehn GT, Suffredini AF. Quality control of serum albumin depletion for proteomic analysis. Clin Chem 2007; 53(11): 1915-20.

[62] Baussant T, Bouguerellet L, Johnson A, et al. Effective depletion of albumin using a new peptide-based affinity medium. Proteomics 2005; 5(4): 973-7.

[63] Schiess R, Wollscheid B, Aebersold R. Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol 2009; 3(1): 33-44.

[64] Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski JC. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 2003; 107(19): 2403-5.

[65] Quiles J, Roy D, Gaze D, et al. Relation of ischemia-modified albumin (IMA) levels following elective angioplasty for stable angina pectoris to duration of balloon-induced myocardial ischemia. Am J Cardiol 2003; 92(3): 322-4.

[66] Kleinfeld AM, Prothro D, Brown DL, Davis RC, Richieri GV, DeMaria A. Increases in serum unbound free fatty acid levels following coronary angioplasty. Am J Cardiol 1996; 78(12): 1350-6.

[67] de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345(14): 1014-21.

[68] James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003; 108(3): 275-81.

[69] Dagianti A, Penco M, Agati L, et al. Stress echocardiography: comparison of exercise, dipyridamole and dobutamine in detecting and predicting the extent of coronary artery disease. J Am Coll Cardiol 1995; 26(1): 18-25.

[70] Ikonomidou I, Athanassopoulos G, Lekakis J, et al. Myocardial ischemia induces interleukin-6 and tissue factor production in patients with coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2005; 112(25): 3868-75.

[71] Weiss JN, Korge P, Honda HM, Ping P. Role of the mitochondrial permeability transition in myocardial ischemia. Circ Res 2003; 93(4): 292-301.

[72] Shen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 2008; 321(5895): 1493-5.

[73] Jacques S, Yin X, Sicard P, et al. Identification of cardiac myosin binding protein C as a candidate biomarker of myocardial infarction by proteomic analysis. Mol Cell Proteomics 2009; 8(12):2687-99.

[74] Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1(11): 845-67.

[75] Sabatine MS, Liu E, Morrow DA, et al. Metabolic identification of novel biomarkers of myocardial ischemia. Circulation 2005; 112(25): 3868-75.

[76] Beretta L. Proteomics from the clinical perspective: many hopes and much debate. Nat Method 2007; 4(10): 785-6.

[77] Zhang H, Liu AY, Loriaux P, et al. Mass spectrometric detection of tissue proteins in plasma. Mol Cell Proteomics 2007; 6(1): 64-71.

[78] Stasny J, Fosslien E, Robertson AL, Jr. Human aortic intima protein composition during initial stages of atherogenesis. Atherosclerosis 1986; 60(2): 131-9.

[79] You SA, Archacki SR, Angheloiu G, et al. Proteomic approach to coronary atherosclerosis shows ferritin light chain as a significant marker: evidence consistent with iron hypothesis in atherosclerosis. Physiol Genomics 2003; 13(1): 25-30.

[80] Perlman DH, Bauer SM, Ashrafian H, et al. Mechanistic insights into nitrite-induced cardioprotection using an integrated metabolomic/proteomic approach. Circ Res 2009; 104(6): 796-804.

[81] Zlatkovic J, Arrell DK, Kane GC, Miki T, Seino S, Terzic A. Proteomic profiling of KATP channel-deficient hypertensive heart maps risk for maladaptive cardiomyopathic outcome. Proteomics 2009; 9(5): 1314-25.

[82] Grant JE, Bradshaw AD, Schwacek JH, Baicu CF, Zile MR, Schey KL. Quantification of Protein Expression Changes in the Aging Left Ventricle of Rattus norvegicus. J Proteome Res 2009; 8(9):4252-63.

[83] Costa VM, Silva R, Tavares LC, et al. Adrenaline and reactive oxygen species elicit proteome and energetic metabolism modifications in freshly isolated rat cardiomyocytes. Toxicology 2009; 260(1-3): 84-96.

[84] Ruse CI, Tan FL, Kinter M, Bond M. Integrated analysis of the human cardiac transcriptome, proteome and phosphoproteome. Proteomics 2004; 4(5): 1505-16.

[85] Kutuk R, Xu X, Whitnall M, Kashem MA, Vyoral D, Richardson DR. Proteinomic analysis of hearts from frataxin knockout mice: marked rearrangement of energy metabolism, a response to cellular stress and altered expression of proteins involved in cell structure, motility and metabolism. Proteomics 2008; 8(8): 1731-41.

[86] Chu G, Kerr JP, Mitton B, et al. Proteomic analysis of hyperdynamic mouse hearts with enhanced sarcoplasmic reticulum calcium cycling. FASEB J 2004; 18(14): 1725-7.

[87] Labugger R, Simpson JA, Quick M, et al. Strategy for analysis of cardiac troponins in biological samples with a combination of affinity chromatography and mass spectrometry. Clin Chem 2003; 49(6 Pt 1): 873-9.

[88] Zabrouskov V, Ge Y, Schwartz J, Walker JW. Unraveling molecular complexity of phosphorylated human cardiac troponin I by top down electron capture dissociation/electron transfer dissociation mass spectrometry. Mol Cell Proteomics 2008; 7(10): 1838-49.

[89] Hamblin M, Friedman DB, Hill S, Caprioli RM, Smith HM, Hill MF. Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy. J Mol Cell Cardiol 2009; 48(6 Pt 1): 873-9.

[90] Duan X, Young R, Straubinger RM, et al. A straightforward and highly efficient precipitation/on-pellet digestion procedure coupled with a long gradient nano-LC separation and Orbitrap mass spectrometry for label-free expression profiling of the swine heart mitochondrial proteome. J Proteome Res 2009; 8(6): 2838-50.

[91] Meng C, Jin X, Xia L, et al. Alterations of mitochondrial enzymes contribute to cardiac hypertrophy before hypertension development in spontaneously hypertensive rats. J Proteome Res 2009; 8(5): 2463-75.